<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="185839">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00674570</url>
  </required_header>
  <id_info>
    <org_study_id>H841-31915-01A</org_study_id>
    <nct_id>NCT00674570</nct_id>
  </id_info>
  <brief_title>Veteran Stress and Learning Study</brief_title>
  <acronym>VSL</acronym>
  <official_title>Effects of Hydrocortisone and D-Cycloserine on Fear Extinction in Veterans With Posttraumatic Stress Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study examining the use of two medications, Hydrocortisone and
      D-Cycloserine, compared to an inactive substance (placebo), on their ability to reduce fear
      responses and memory of fear in Veterans with symptoms of Posttraumatic Stress Disorder
      (PTSD). These responses will be tested using a fear learning and memory task administered by
      computer.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2008</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Participant, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skin Conductance</measure>
    <time_frame>Day 7, 9, 16</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Day 7, 9, 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eye Blink</measure>
    <time_frame>Day 7, 9, 16</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Stress Disorders, Posttraumatic</condition>
  <arm_group>
    <arm_group_label>Arm 1: Hydrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydrocortisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: D-Cycloserine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D-Cycloserine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>25 mg/oral one hour prior to extinction task</description>
    <arm_group_label>Arm 1: Hydrocortisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-Cycloserine</intervention_name>
    <description>50 mg/oral one hour prior to extinction task</description>
    <arm_group_label>Arm 2: D-Cycloserine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One hour prior to extinction task</description>
    <arm_group_label>Arm 3: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Veterans and civilians with an age range of 18 to 65 years

          -  Participants must be physically healthy volunteers

        Exclusion Criteria:

          -  Individuals who fall outside the age range

          -  Individuals with medical conditions that would interfere with participation

          -  Other criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabra S Inslicht, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Francisco VA Medical Center, San Francisco, CA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco VA Medical Center, San Francisco, CA</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Inslicht SS, Metzler TJ, Garcia NM, Pineles SL, Milad MR, Orr SP, Marmar CR, Neylan TC. Sex differences in fear conditioning in posttraumatic stress disorder. J Psychiatr Res. 2013 Jan;47(1):64-71. doi: 10.1016/j.jpsychires.2012.08.027. Epub 2012 Oct 26.</citation>
    <PMID>23107307</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 13, 2017</lastchanged_date>
  <firstreceived_date>May 6, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stress Disorders, Posttraumatic</keyword>
  <keyword>Hydrocortisone</keyword>
  <keyword>Cycloserine</keyword>
  <keyword>Extinction, Psychological</keyword>
  <keyword>PTSD</keyword>
  <keyword>San Francisco</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cycloserine</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
